| Literature DB >> 22611353 |
Zeping Xie1,2, Bing Liu1, Hongpeng Wang3, Shengxiang Yang4, Hongyu Zhang1,2, Yipeng Wang1, Naiyun Ji1, Song Qin1, Hartmut Laatsch3.
Abstract
Kiamycin (1), a new angucyclinone derivative possessing an 1,12-epoxybenz[a]anthracene ring system, was isolated from the marine Streptomyces sp. strain M268 along with the known compounds 8-O-methyltetrangomycin (3) and 8-O-methylrabelomycin (4). Their structures were elucidated by detailed spectroscopic analysis and comparison with literature data. The new angucyclinone derivative showed inhibitory activities against the human cell lines HL-60 (leukemia), A549 (lung adenocarcinoma), and BEL-7402 (hepatoma) with inhibition rates of 68.2%, 55.9%, and 31.7%, respectively, at 100 µM. It appears to have potential as an anticancer agent with selective activity.Entities:
Keywords: angucyclinone; cytotoxicity; epoxybenz[a]anthracene; marine Streptomyces
Mesh:
Substances:
Year: 2012 PMID: 22611353 PMCID: PMC3347014 DOI: 10.3390/md10030551
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Structures of kiamycin (1); gephyromycin (2); 8-O-methyltetrangomycin (3); and 8-O-methylrabelomycin (4).
1H, 13C, Correlated Spectroscopy (COSY) and Heteronuclear Multiple Bond Correlation (HMBC) NMR data of kiamycin (1) in CDCl3.
| Position | δC, assignm. | δH, mult. (
| 1H–1H COSY | HMBC |
|---|---|---|---|---|
| 1 | 156.7, Cq | |||
| 2 | 110.5, CH | 6.41, s br | H-4, 3-CH3 | C-1, C-4, C-12b, 3-CH3 |
| 3 | 140.1, Cq | |||
| 4 | 117.6, CH | 6.50, s br | H-2, 3-CH3 | C-2, C-5, C-12b, 3-CH3 |
| 4a | 131.5, Cq | |||
| 5 | 130.0, CH | 6.74, d (9.5) | H-6 | C-4, C-4a, C-6a, C-12b |
| 6 | 134.9, CH | 5.88, d (9.5) | H-5 | C-4a, C-12a |
| 6a | 75.8, Cq | |||
| 7 | 66.4, CH | 4.85, d (1.5) | H-12a | C-6a, C-7a, C-8, C-11a, C-12a |
| 7a | 125.5, Cq | |||
| 8 | 158.3, Cq | |||
| 9 | 111.0, CH | 6.85, d (8.3) | H-10, H-11 | C-7a, C-8, C-11 |
| 10 | 130.1, CH | 7.38, t (7.9) | H-9, H-11 | C-8, C-11a |
| 11 | 123.3, CH | 7.18, d (7.9) | H-9, H-10 | C-7a, C-9, C-12 |
| 11a | 133.0, Cq | |||
| 12 | 82.6, CH | 6.00, d (10.4) | H-12a | C-1, C-6a, C-7a, C-11, C-11a, C-12a, C-12b |
| 12a | 44.0, CH | 4.11, d (10.4) | H-7, H-12 | C-6a, C-7, C-11a, C-12b |
| 12b | 122.0, Cq | |||
| 8-OCH3 | 55.9, CH3 | 3.80, s | C-8 | |
| 3-CH3 | 22.0, CH3 | 2.24, s | H-2, H-4 | C-2, C-3, C-4 |
Figure 2HMBC and COSY correlations (left) and NOESY correlations (right) of kiamycin (1).
Figure 3Partial structure 5 of kiamycin (1) with four open valences; C* = oxygenated carbon; 6 = X-14881F.
Figure 4Hypothetical biotransformation of panglimycin B (7) into kiamycin (1).
Cytotoxicity of kiamycin (1) and adriamycin against human cell lines HL-60 (leukemia), BEL-7402 (hepatoma), and A549 (lung adenocarcinoma) at 10−4 M.
| Cancer Cell Line | Inhibition Rate by 1 (%) | Inhibition Rate by Adriamycin (%) |
|---|---|---|
| human leukemic cell line HL-60 | 68.8 | 70.0 |
| human hepatoma cell line BEL-7402 | 31.7 | 79.3 |
| human lung adenocarcinoma cell line A549 | 55.9 | 80.8 |